Latest News Archive

Please select Category, Year, and then Month to display items

PhD study investigates cannabis as potential cancer treatment

12 December 2024 | Story André Damons | Photo André Damons

A lecturer and researcher from the University of the Free State (UFS) Department of Pharmacology hopes her research into the use of cannabis in reversing anticancer drug resistance is a step forward into treating various cancers especially in Southern Africa.

Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with the degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. She started her career as a research scientist in the area of African traditional medicines in 2018 and her research received both national and international recognition.

“It’s an amazing (feeling to graduate today). My PhD journey was smooth and beautiful and with mentorship of Prof (Motlalepula) Matsabisa, who groomed me well, I did not shed a tear,” said Dr Mangoato. Dr Gudrun S Ulrich-Merzenich from the University of Bonn in Germany, was her co-supervisor with Prof Matsabisa.

According to the graduation programme, Dr Mangoato, Lecturer and Researcher in the UFS Department of Pharmacology, with her thesis titled Investigating the anticancer and possible resistant reversal effects of cannabis sativa l. extracts in cervical cancer cell lines and modulation of ABC transporters comprehensively explored the therapeutic potential of Cannabis sativa L. in overcoming drug resistance in cervical cancer using in vitro and network pharmacology approaches.

A step forward for treating various cancers

The research looked at the chemical fingerprints and pharmacological targets of C. sativa L. extracts, highlighting its antiproliferative properties against normal non-cancerous cells, cervical cancer cells and the cisplatin-resistant cervical cancer cells. Through PCR analysis, distinct gene expression profiles were identified, revealing the potential effects of combination treatments to counteract cisplatin resistance by downregulating genes associated with drug transporters and crucial signalling pathways. This work provides valuable insights into innovative therapeutic strategies for improving cervical cancer treatment, highlighting new avenues for overcoming resistance and enhancing treatment efficacy though the possible use of plant extracts.

“I hope my research takes a step forward in treating various cancers – especially gynaecology cancers in the Southern Hemisphere in Africa. Hopefully the research can later transcend into clinical trials and hopefully influence more policymakers. We also hope to further develop cannabis to be used as an adjuvant therapy for those drugs that are failing to treat cancer,” says Dr Mangoato, who was the recipient of the Women in Science Master’s Student in 2018.

Her graduation was also a proud moment for Prof Matsabisa, an expert in traditional African medicine, who was like a father to her during her studies. “Prof identified me from my honours degree and walked this journey with me. He has been a great mentor, a father and an amazing supervisor.”

Dr Mangoato says she will for now focus on research only and helping and monitoring upcoming researchers, especially female researchers as there is a scarcity of them her field.

News Archive

SADoCoL receives partial reinstatement of blood sample testing by the World Anti-Doping Agency

2016-08-22

Last week, the World Anti-Doping Agency (WADA) announced the lifting of the suspension of blood sample analysis by the South African Doping Control Laboratory (SADoCoL) at the University of the Free State (UFS). Although the suspension of urine sample analysis is still under review, the UFS is appreciative of the new outcome. The initial temporary suspension of SADoCoL, announced on 3 May 2016, included the suspension of all doping-control procedures which applied to both urine and blood samples.

The main reason for the suspension involved analytical techniques relevant to urine analysis; however, the testing of blood samples was also included in the suspension. At the time of the suspension, no adverse findings were reported for the laboratory in relation to blood-sample testing for Athlete Blood Passport (ABP) assessment.

According to the agreement with WADA, the suspension period would be utilised to implement and test new systems in order to achieve the standard presently required by WADA, as well as to perform development and improvements. SADoCoL is a specialised service laboratory of the UFS and has been in existence for more than thirty years.

Upon SADoCoL’s request to lift the suspension of only the ABP analysis, WADA agreed to allow the laboratory to apply for reaccreditation. SADoCoL immediately applied for reaccreditation of ABP analysis on blood, so that the laboratory would be allowed to at least offer this service to the Anti-Doping community in Africa.

For this purpose, inspections were performed by the South African National Accreditation System (SANAS) and by WADA, during which all aspects of blood analysis by the laboratory were thoroughly assessed and tested. The successful outcome of these inspections resulted in the reaccreditation of SADoCoL by WADA in order to perform ABP analysis as required by the WADA International Standard for Laboratories, with effect from 4 August 2016.

This outcome allows the laboratory to once again perform this very essential analytical procedure. The South African Institute for Drug-Free Sport (SAIDS) and other regular users can now continue to send blood samples to SADoCoL for ABP analysis, instead of making use of alternative laboratories.

Released by: Lacea Loader (Director: Communication and Brand Management)
Tel: +27 51 401 3422/2707 or +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept